Clinical Trial: Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Study Status: Available
Recruit Status: Available
Study Type: Expanded Access
Official Title: Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)
Brief Summary: Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.
Detailed Summary:
Sponsor: Merck KGaA
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Merck KGaA
Dates:
Date Received: March 20, 2017
Date Started:
Date Completion:
Last Updated: May 8, 2017
Last Verified: March 2017